BridgeBio Pharma has caught Wall Street’s attention after the company shared positive Phase 3 results from its FORTIFY trial for BBP-418 in limb-girdle muscular dystrophy type 2I/R9. The treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback